Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT trial, assessing Aspaveli (pegcetacoplan) in treating C3 glomerulopathy (C3G) ...
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty ...
Selecta Biosciences and Sobi have laid down a marker in their attempt to challenge Horizon for the gout market, delivering phase 3 data that suggest their SEL-212 candidate can match the efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback